Skip to main content
. Author manuscript; available in PMC: 2011 Sep 9.
Published in final edited form as: Sci Transl Med. 2010 Nov 3;2(56):56ra81. doi: 10.1126/scitranslmed.3001417

Fig. 5.

Fig. 5

Plasma levels of cholesterol oxidation products in human subjects with diabetes and coronary artery disease.

(A) Plasma 7-KC and 3β,5α,6β-triol levels re-plotted for individual control and NPC1 subjects (heterozygote subjects have been omitted), (B) Plasma 7-KC and 3β,5α,6β-triol levels plotted for individual control and diabetic (DM) subjects (n=34), which have been matched for age, gender, smoking status and statin usage. (C) Plasma 7-KC and 3β,5α,6β-triol levels plotted for individual control subjects and subjects with angiographically-proven coronary artery disease (CAD) (n=18), which have been matched for age, gender, smoking status and statin usage.